[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"young-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:young-adult":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,45,84,108,140,171,206,227,248,284],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100606695","designing-a-smoking-intervention-for-youth-smokers-100606695",false,"NCT07178899","Designing a Smoking Intervention for Youth Smokers","Designing a Smoking Intervention for Youth Smokers Using Q-Methodology: A Pilot Randomized Controlled Trial","Inclusion Criteria (Phase 1):\n\n* Hong Kong citizens\n* Have ever habitually used conventional cigarettes in the past year\n* Not using cigarettes for the past 7-30 days\n* Aged 25 or below (parental consent is required for participants under 18 years old)\n* No barriers in communicating in Cantonese and reading and writing Chinese\n* Quit smoking without using cessation services\n\nInclusion Criteria (Phase 3):\n\n* Hong Kong citizens\n* Have ever habitually used conventional cigarettes in the past year\n* Received at least 4 weeks of smoking cessation service before enrolling into the study\n* abstained from tobacco use for 7 days without concurrent use of any cessation services\n* Aged 25 or below (parental consent is required for participants under 18 years old)\n* No barriers in communicating in Cantonese and reading and writing Chinese\n\nExclusion Criteria (Phase 1 \\& 3):\n\n* Have unstable physical or psychological conditions as advised by doctors or counsellors\n* Are users of illicit drugs (e.g., heroin, marijuana, ketamine, etc.)\n* Have become pregnant in the past two months\n* unable to communicate in Cantonese and read Chinese\n\nInclusion Criteria (Phase 2) (for SC counsellors) :\n\n* SC counsellors from local SC clinics under HKU Youth Quit Line, Tung Wah Group of Hospitals Integrated Center on Smoking Cessation and United Christian Nethersole Community Health Service",true,"ALL","25 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to develop a typology-based intervention delivered by smoking cessation (SC) counsellors to prevent smoking relapse in ex-smokers who recently quit. The two main research questions include (1) Can a typology-based smoking relapse prevention intervention be feasible and accepted by the smokers and SC counsellors who deliver the new intervention? (2) What is the preliminary evidence on the efficacy of the typology-based smoking relapse prevention to increase tobacco abstinence in ex-smokers who have recently quit? If the intervention shows at least a small effect size (i.e. risk ratio\\>1.3), or the intervention is feasible while modifications can potentially increase the efficacy, a future definitive RCT is warranted.",[27,28,29],"Smoking (Tobacco) Addiction","Young Adult","RCT",[31,28,29],"Smoking Cessation","NOT_YET_RECRUITING","2026-05-29",{"date":35,"type":36},"2026-06-02","ACTUAL",{"date":38,"type":21},"2026-06-05",{"date":40,"type":21},"2027-06-30",{"name":42,"class":43},"The University of Hong Kong","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100625550","phase-2-intratumoral-dnx-2401-for-high-grade-pediatric-brain-tumors-100625550","NCT07424092","Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors","Intratumoral DNX-2401 Administration for Recurrent and Refractory High Grade Brain Tumors in Pediatric and Young Adult Patients","PED-DNX2401","Inclusion Criteria:\n\n* The participant or participant's parents or legally acceptable representatives (if applicable) provides written informed consent for the trial and the pediatric participant provides writ-ten assent, where applicable, based on age and country requirements.\n* Patients with recurrent or refractory high grade malignant brain tumors (high grade glioma, embryonal CNS tumors \\[medulloblastomas, ATRT, EMTR, pineoblastoma\\], and ependymomas) diagnosis based on initial histopathological diagnosis and further clinical and radiological fol-low-up, in whom gross total resection is not feasible, and with a life expectancy of at least 16 weeks at the time of consent.\n* Recurrences within the radiation field will be considered if there is confirmed growth of the lesion in two consecutive MRI or if they occur at least 12 weeks after completion of ra-diation therapy, or if there is clear histopathological confirmation of tumor recurrence.\n* Male and female participants age ≥ 1 years and ≤ 25 years.\n* A single measurable lesion longer than 10 mm in two perpendicular diameters, considered by the investigator to be accessible for safe stereotactic biopsy and virus injection.\n* Lansky Performance Status (LPS) ≥ 60 for participants \\\u003C 16 years, or Karnofsky Performance Status (KPS) ≥ 60 for participants ≥ 16 years.\n* No other chemotherapy or immunotherapy in the 4 weeks before inclusion.\n* Steroids: free off or requiring decreasing or stable corticosteroid dose (≥ 0.05 mg\u002Fkg dexa-methasone daily, or equivalent for other steroids) in the 2 weeks before DNX-2401 admin-istration.\n* Radiation: no craniospinal irradiation, total body irradiation nor focal irradiation in the 6 weeks before inclusion.\n* Autologous Stem Cell Transplantation: patients must be ≥ 3 months post-transplant prior to entry of the study.\n* Patients must be fully recovered from all acute treatment related toxicities of all prior therapies.\n* Laboratory test: adequate hematological (platelets ≥ 100x10e9\u002FL, neutrophils ≥ 1.0x10e9\u002FL, hemoglobin ≥ 5,6 mmol\u002FL), renal function (creatinine \\\u003C1.5 times ULN) and liver function (≤3 times ULN) values.\n* Negative pregnancy test for female participants of child-bearing potential, where child-bearing potential is defined as a fertile female who is pubertal or post-pubertal and not permanently sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy).\n* Female participants of child-bearing potential, who are sexually active, agree to use ac-ceptable birth control starting at informed consent and continuing for at least 120 days af-ter DNX-2401 administration. Male participants agree to use acceptable birth control start-ing at informed consent and continuing for at least 90 days after DNX-2401 administration.\n\nExclusion Criteria:\n\n* Any medical or psychological condition or disease that might interfere with the subject's ability to participate or give informed consent (if older than 16 years).\n* Spinal location, or lesions considered risky for stereotactic injection of virus or that might favor entrance of the virus in the ventricular system.\n* Any treatment outside the allowable guidelines outlined in the inclusion criteria.\n* Severe acute infection or intercurrent medical condition including, but not limited to se-vere renal, hepatic, heart or bone marrow failure that based on investigator discretion do not permit inclusion in the study.\n* Subjects with immunodeficiency or autoimmune conditions, active hepatitis or known HIV. No testing for Hepatitis B, Hepatitis C and HIV is required unless mandated by local health authority.\n* Subjects with another primary malignancy.\n* Prior history of encephalitis, multiple sclerosis or other CNS infections or primary CNS dis-ease that would interfere with evaluation.\n* Li Fraumeni Syndrome or a known germ line deficit in the retinoblastoma gene or its relat-ed pathways.\n* Concurrent therapy with any antiviral drug or any immunosuppressive drug (except ster-oids).\n* Life or life-attenuated vaccinations within 30 days prior to DNX-2401 administration and while participating in the study. Killed vaccines are permitted.\n* Prior participant in experimental viral therapy.\n* Inability to undergo MRI scans for any reason.\n* Pregnancy or breastfeeding.","1 Year",{"count":55,"type":21},39,[57],"PHASE2","The goal of this clinical trial is to learn if intratumoral administration of DNX-2401 works to treat recurrent and refractory high grade brain tumors in children and young adults. It will also learn about the safety of DNX-2401.\n\nThe main questions it aims to answer are:\n\n* Does a single intratumoral administration of DNX-2401 elicit tumor response and improve survival?\n* Is a single intratumoral administration of DNX-2401 safe and well tolerated?\n\nParticipants will:\n\n* Undergo surgery for tumor biopsy followed by a single intratumoral administration of DNX-2401\n* Visit the clinic periodically for checkups and tests",[60,61,62,63,64,65,28],"High Grade Glioma","Ependymoma","Embryonal Tumor of Brain","Recurrence","Refractory","Pediatric",[67,60,61,68,69,70,71,72],"High Grade Brain Tumors","Embryonal CNS Tumors","Recurrent or refractory","Pediatric and young adult patients","Oncolytic virus","DNX-2401","RECRUITING","2026-05-21",{"date":76,"type":36},"2026-05-27",{"date":78,"type":36},"2026-05-12",{"date":80,"type":21},"2029-05",{"name":82,"class":43},"Clinica Universidad de Navarra, Universidad de Navarra",2,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":16,"sex":17,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":95,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":106,"locationsCount":44},"100636687","plantar-pressure-and-pain-in-young-adults-100636687","NCT07568925","Plantar Pressure and Pain in Young Adults","Investigation of the Relationship Between Plantar Pressure Distribution and Pain Localization and Severity in Young Adults","Inclusion Criteria:\n\n* Young adults aged between 18 and 35 years\n* Ability to stand and walk independently\n* Adequate cognitive function to understand and follow the measurement procedures\n* Willingness to participate voluntarily and provide written informed consent\n* Absence of acute lower extremity pain or injury on the day of assessment\n* Not using any assistive devices (e.g., orthoses, canes) during measurement\n\nExclusion Criteria:\n\n* History of a foot deformity diagnosed during childhood\n* History of musculoskeletal injury involving the lower extremity or lumbar region within the past 12 months\n* Previous surgery involving the lower extremity or lumbar region\n* Any condition that may affect general motor function, balance, circulation, sensory function, or pain perception","18 Years","35 Years",{"count":94,"type":21},53,"1 Day","OBSERVATIONAL","The musculoskeletal system represents a holistic movement organization emerging from the integrated function of the central nervous system, musculoskeletal structures, and joint complexes. This organization is defined in the literature as the kinetic chain, characterized by the sequential and coordinated activation of body segments to enable distal segments to perform activities with optimal speed, position, and timing. The efficiency of the kinetic chain depends on optimal length-tension relationships, neuromuscular control, and balanced load transfer between segments. As the initial point of contact with the ground, the foot functions not merely as a passive support surface but as a dynamic structure actively involved in postural control, balance, and the regulation of ground reaction forces. Plantar pressure distribution and Center of Pressure (CoP) dynamics are considered objective indicators of foot-ground interaction. Due to its complex anatomical and biomechanical structure, any mechanical disturbance within the foot can influence the loading patterns of the entire kinetic chain.Abnormal plantar pressure distribution-characterized by increased peak pressures, altered forefoot-rearfoot load ratios, and increased CoP variability-may lead to compensatory load redistribution in proximal joints. These compensations have been associated with altered motor strategies, reduced neuromuscular control, and impaired shock absorption. Consequently, such alterations may contribute to the development of pain in proximal regions. This suggests a potential association between plantar pressure patterns and pain localization and severity in young adults.",[28,99,100],"Plantar Pressure Distrubution","Pain","2026-05-01",{"date":103,"type":36},"2026-05-06",{"date":101,"type":21},{"date":101,"type":21},{"name":107,"class":43},"Fenerbahce University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":92,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":44},"100559370","phase-2-brentuximab-vedotin-for-newly-diagnosed-chl-in-chinese-caya-based-on-petct-assessment-100559370","NCT06563245","Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET\u002FCT Assessment","A Phase II\u002FIII Study of Brentuximab Vedotin for Newly Diagnosed Classical Hodgkin Lymphoma in Chinese CAYA Based on PET\u002FCT Assessment","Inclusion Criteria:\n\n* Ages \\>=2\\~\\\u003C35 years at the time of enrollment;\n* Patients with newly diagnosed, pathologically confirmed classical Hodgkin lymphoma (HL) by at least 2 tertiary referral centers for pathology;\n* Adequate organ function;\n* Patients and\u002For their parents or legal guardians sign a written informed consent;\n\nExclusion Criteria:\n\n* Patients with nodular lymphocyte-predominant HL;\n* Patients with an immunodeficiency that existed prior to diagnosis; such as primary immunodeficiency syndromes, organ transplant recipients and children on current systemic immunosuppressive agents are not eligible;Patients known to be positive for HIV are not eligible.\n* Patients who are pregnant; Lactating females who plan to breastfeed.\n* Patients who received systemic corticosteroids within 28 days of enrollment on this protocol","2 Years",{"count":117,"type":21},96,[57,119],"PHASE3","Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.",[122,123,124,28,125,126,127,128,129],"Classical Hodgkin Lymphoma","Child","Adolescent","Metabolic Response","Survival","Treatment","Brentuximab Vedotin","PET Scan","2026-03-17",{"date":132,"type":36},"2026-03-19",{"date":134,"type":36},"2024-09-25",{"date":136,"type":21},"2039-11-15",{"name":138,"class":139},"Children's Cancer Group, China","NETWORK",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":83},"100477022","alcohol-roc-training-100477022","NCT05491551","Alcohol-ROC-Training","Brief Training for Heavy Drinking Young Adults: Regulation of Alcohol Craving","A-ROC-T","Inclusion Criteria:\n\n(1) Young adults ages 18-26 years, who (2) report ≥ 3 heavy drinking days (i.e., heavy drinking defined by \\>3 drinks for women, \\>4 drinks for men) in the prior month; (3) are motivated to quit or reduce drinking; (4) are fluent in English and have a 6th grade or higher reading level; (5) have access to a computer with working internet; (6) use a working smartphone; (7) can commit to the full length of the protocol; and (8) are willing to be randomized to intervention condition.\n\nExclusion Criteria:\n\n(1) Current (past 12 months) clinically-severe alcohol use disorder (AUD; e.g., history of seizures, delirium, or hallucinations during withdrawal) or current severe alcohol withdrawal; (2) Current (past 12 months) clinically-severe substance use disorder (except tobacco) or current severe drug withdrawal; (3) serious other psychiatric illness by history or examination; (4) severe or unstable physical disease within the past 6 months; (5) psychoactive medications (e.g., mood stabilizers) that have not been at a stable dose unless determined to be on a stable dose of medication by the study psychiatrist; (6) current use of any investigational medication; (7) color blindness; (8) biological females who are pregnant; and (9) notable dislike to any particular type of alcoholic beverage depicted in study stimuli; (10) Participants who will not complete at least 70% of past day EMA reports in the pre-intervention phase will not be randomized; (11) Participants who cannot understand or follow study-related instructions (e.g., unable to correctly use the intervention strategies, indicate lack of understanding of study instructions despite multiple attempts).","26 Years",{"count":150,"type":21},177,[24],"The goal of the proposed study is to examine whether brief training in regulation of craving (ROC-T) affects alcohol drinking. The study will consist of a basic screening (phone and online), and in person visit to determine eligibility and conduct pre-intervention baseline assessments, 1-4 training (ROC-T) visits, a post-intervention assessment visit, and 1-2 phone\u002Fonline follow up assessments.The two active conditions of ROC-T are based on cognitive-behavioral treatments (CBT) and mindfulness-based treatments (MBT).",[154,155,28,156],"Binge Drinking","Heavy Drinking","Heavy Drinker",[154,155,28,156,158,159,160,161],"Regulation of Craving","Cognitive Behavioral Therapy","Neurocognitive Training","Mindfulness-Based Therapy","2026-02-17",{"date":164,"type":36},"2026-02-19",{"date":166,"type":36},"2022-09-28",{"date":168,"type":21},"2027-12",{"name":170,"class":43},"Yale University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":189,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":83},"100606257","optimizing-the-aya-survivors-coping-and-emotional-needs-toolkit-100606257","NCT07173205","Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit","R00 Full Factorial Trial: Optimizing ASCENT","ASCENT","Inclusion Criteria:\n\n* Age at enrollment (adolescents 15-17, emerging adults 18-25, young adults 26-39)\n* Age at diagnosis (adolescents 12-17, emerging adults 15-25, young adults 15-39)\n* Time since completion of treatment: 1 month to 5 years\n* Language: Fluent in English (spoken and written)\n* Technology: Own smart phone with data plan\n\nExclusion Criteria:\n\n* Mental Health: Current diagnosis of severe or persistent mental illness\n* Suicidality: Severe suicidal ideation (including plan and intent)","15 Years","39 Years",{"count":182,"type":21},208,[24],"Our team has developed a digital intervention that aims to help adolescent and young adult cancer survivors (AYAs) manage symptoms of depression. This tool includes one psychoeducation component and four components that are based on evidence-based interventions for depression. The goal of this study is to test which component or combination of components meaningfully contribute to improvements in depressive symptoms among AYAs.",[186,187,124,28,188],"Depression","Cancer","Adult",[190,191,192,193,194,195,196],"AYA","Adolescent and Young Adult","Cancer Survivorship","Depressive Symptoms","Digital Mental Health","Multiphase Optimization Strategy","Full Factorial Trial","2026-01-05",{"date":199,"type":36},"2026-01-07",{"date":201,"type":36},"2025-10-25",{"date":203,"type":21},"2027-03",{"name":205,"class":43},"East Carolina University",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":16,"sex":17,"minAge":91,"maxAge":18,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":44},"100616719","comparing-the-effects-of-smart-app-assited-super-slow-jogging-and-stationary-cycling-on-respiratory-function-and-aerobic-fitness-in-college-students-100616719","NCT07309263","Comparing the Effects of Smart App-Assited Super-Slow Jogging and Stationary Cycling on Respiratory Function and Aerobic Fitness in College Students","Inclusion Criteria:\n\n* required no regular exercise training in the past six months\n* ability to safely perform high-intensity cycling exercise\n\nExclusion Criteria:\n\n* musculoskeletal limitations that prevented cycling exercise\n* recent infection\n* known cardiopulmonary disease or medical history affecting cardiovascular or respiratory function\n* smoking\n* use of medications that may influence cardiopulmonary responses to exercise\n* other contraindications to exercise testing according to the American College of Sports Medicine (ACSM) guidelines",{"count":213,"type":21},60,[24],"As health awareness continues to rise, more people are prioritizing exercise to improve physical condition and enhance overall fitness. For those lacking exercise habits, selecting a simple, accessible, and effective workout becomes crucial. Against a backdrop of prolonged sitting and inactivity, \"super slow jogging\" is gaining attention. This aerobic exercise involves a slow walking pace and low intensity, yet burns more calories than regular walking, making it an ideal entry-level activity for beginners or those with lower fitness levels. This study aims to investigate whether incorporating super slow jogging training can effectively enhance cardiorespiratory fitness and respiratory function, comparing its outcomes with other exercise types. The purpose of this experiment is academic research, primarily exploring the impact of exercise intervention on physiological functions. It is not intended for health screening or medical diagnosis.",[217,28],"Sedentary Lifestlye","2025-12-29",{"date":220,"type":36},"2025-12-30",{"date":222,"type":36},"2025-11-20",{"date":224,"type":21},"2026-02-28",{"name":226,"class":43},"Fooyin University",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":233,"enrollmentInfo":234,"targetDuration":236,"studyType":96,"phases":4,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":44},"100617271","risk-prediction-of-disease-progression-in-early-onset-coronary-atherosclerosis-100617271","NCT07316452","Risk Prediction of Disease Progression in Early-Onset Coronary Atherosclerosis","Inclusion Criteria:\n\n1. Age between 18 and 45 years at the time of enrollment.\n2. Presence of symptoms suggestive of coronary artery disease and completion of coronary computed tomography (CT) examination.\n3. Ability and willingness to provide written informed consent and to participate in follow-up assessments.\n\nExclusion Criteria:\n\n1. Inability or unwillingness to complete follow-up assessments.\n2. Inability to provide written informed consent.\n3. History of coronary revascularization, including percutaneous coronary intervention or coronary artery bypass grafting.\n4. Poor-quality coronary computed tomography images that are inadequate for reliable plaque assessment.\n5. Presence of severe systemic disease with limited life expectancy that may interfere with study follow-up.\n6. Pregnant or breastfeeding women.\n7. Participation in another clinical study that may interfere with the outcomes of this study.","45 Years",{"count":235,"type":21},10000,"3 Years","This study is part of a nationwide research project in China that aims to better understand how coronary artery disease develops and progresses in young adults. The study will enroll approximately 10,000 participants aged 45 years or younger who undergo coronary CT scans at multiple hospitals across China.\n\nInformation collected at enrollment includes basic health information, cardiovascular risk factors, blood test results, medication use, lifestyle habits, and, for some participants, genetic data. Participants will undergo follow-up coronary CT scans after several years to evaluate changes in coronary artery plaque and disease progression.\n\nBy analyzing these clinical and imaging data, the study aims to identify factors associated with disease progression and to develop prediction models that may help estimate an individual's future risk of coronary plaque progression and cardiovascular events. The results of this study may contribute to improved risk assessment and early prevention strategies for coronary artery disease in young populations.",[239,28],"Coronary Disease","2025-12-19",{"date":197,"type":36},{"date":243,"type":36},"2025-01-01",{"date":245,"type":21},"2028-01-01",{"name":247,"class":43},"Fu Wai Hospital, Beijing, China",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":16,"sex":17,"minAge":91,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":265,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":44},"100593709","an-exploratory-feasibility-study-100593709","NCT07009964","An Exploratory Feasibility Study","AI-Enhanced Educational Intervention to Support Contextual Well-being in Young Adults (ContextWell)","Contextwell","Inclusion Criteria:\n\nPrimarily healthcare students, young adults enrolled in higher education (18-30 years old)\n\nAccess to a computer or mobile device with an internet connection;\n\nWillingness to participate in the educational webinar;\n\nWillingness to complete AI-driven assignments;\n\nAble to read and understand English.\n\nExclusion Criteria:\n\nAre under the age of 18, or above 30;\n\nInability to access a computer or mobile device with internet connection;\n\nInability to read or understand English;\n\nUnwillingness to participate in the webinar or complete assignments.","30 Years",{"count":258,"type":21},12,[24],"This study explores the feasibility of ContextWell, a well-being education programme that combines an online webinar with an AI-powered behavioural nudging system. The programme aims to support university students, particularly those in healthcare disciplines, in enhancing well-being and adopting healthier lifestyle habits.\n\nThe primary objective is to determine whether the programme can be feasibly delivered within university settings. A secondary objective is to assess its potential to improve student well-being and encourage behavioural changes aligned with lifestyle medicine principles.\n\nThe intervention builds on the understanding that healthcare professionals' lifestyle habits and well-being have a direct impact on patient care. Focusing on healthcare students helps advance the integration of lifestyle medicine within health education and clinical practice.\n\nThis single-group feasibility study delivers the full intervention to all participants. Students participate in an online well-being webinar and receive AI-generated behavioural prompts designed to promote self-awareness and healthier daily choices.\n\nKey evaluation measures will indicated the feasibility of the programme among young adults in academic environments. Participant feedback and initial outcomes will support future development and inform larger-scale research.",[262,263,28,264],"Well-Being","Lifestyle, Healthy","Behavior and Behavior Mechanisms",[266,267,268,269,270,271,272,273,274],"Student well-being","Artificial Intelligence","Contextual Well-being","Contextual AI","Preventive health","Digital Health","Lifestyle medicine","Pilot study","Proof of concept","2025-06-18",{"date":277,"type":36},"2025-06-19",{"date":279,"type":21},"2025-11-01",{"date":281,"type":21},"2026-02-01",{"name":283,"class":43},"University College Dublin",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":17,"minAge":256,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":295,"conditions":296,"keywords":302,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":44},"100491743","cardiovascular-longitudinal-alspac-research-investigations-following-hypertensive-pregnancy-in-young-adulthood-100491743","NCT05683093","Cardiovascular Longitudinal ALSPAC Research Investigations Following Hypertensive Pregnancy in Young Adulthood","Cardiovascular Longitudinal the Avon Longitudinal Study of Parents and Children (ALSPAC) Research Investigations Following Hypertensive Pregnancy in Young Adulthood","CLARITY","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Male or female, aged 30 to 40 years at time of enrolment\n* Participant previously took part in the ALSPAC study\n* Able (in the investigator's opinion) and willing to comply with all study requirements\n* Adequate understanding of verbal and written English\n\nExclusion Criteria:\n\n* Pregnant or lactating when they are due to attend for study visit 1\n* Less than six months postpartum\n* Planning to donate blood within two weeks prior to study visit 1\n* Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study\n* Evidence of congenital heart disease or significant chronic disease relevant to cardiovascular or metabolic status\n\nFor exclusion of MRI component only:\n\n* Unsuitable for MRI based on participant screening; the participant may still be included in other parts of the study","40 Years",{"count":294,"type":21},200,"The purpose of this study is to understand more about why young people who were born to a hypertensive pregnancy may have increased risk of high blood pressure and are often at increased risk of heart and blood vessel disease later in life.",[28,297,298,299,300,301],"Hypertension in Pregnancy","Hypertension","Cardiovascular Diseases","Cerebrovascular Diseases","Vascular Diseases",[28,303,297,304,305],"Birth History","Cardiovascular Risk","Exercise Capacity","2023-01-05",{"date":308,"type":36},"2023-01-12",{"date":310,"type":36},"2022-11-17",{"date":312,"type":21},"2027-01-31",{"name":314,"class":43},"University of Oxford"]